Lifeboat Foundation

A speech prosthetic developed by a collaborative team of Duke neuroscientists, neurosurgeons, and engineers can translate a person’s brain signals into what they’re trying to say.

Appearing Nov. 6 in the journal Nature Communications, the new technology might one day help people unable to talk due to neurological disorders regain the ability to communicate through a brain-computer interface.

“There are many patients who suffer from debilitating motor disorders, like ALS (amyotrophic lateral sclerosis) or locked-in syndrome, that can impair their ability to speak,” said Gregory Cogan, Ph.D., a professor of neurology at Duke University’s School of Medicine and one of the lead researchers involved in the project. “But the current tools available to allow them to communicate are generally very slow and cumbersome.”

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Continue reading “Longevity-Associated Triglycerides” »

Skoltech scientists have found a way to improve the most widely used technology for producing single-walled carbon nanotube films—a promising material for solar cells, LEDs, flexible and transparent electronics, smart textiles, medical imaging, toxic gas detectors, filtration systems, and more. By adding hydrogen gas along with carbon monoxide to the reaction chamber, the team managed to almost triple carbon nanotube yield compared with when other growth promoters are used, without compromising quality.

Until now, low yield has been the bottleneck limiting the potential of that manufacturing technology, otherwise known for high product quality. The study has been published in the Chemical Engineering Journal.

Although that is not how they’re really made, conceptually, nanotubes are a form of carbon where sheets of atoms in a honeycomb arrangement—known as graphene—are seamlessly rolled into hollow cylinders.

Discover our selection of discounted synthetic biology tools, perfect for advancing biomedicine, cell-cultured meats, and sustainable textiles.

In our latest feature, we explore the future of gene editing and the challenges we must overcome to harness its full potential.

Living cells are bombarded with many kinds of incoming molecular signal that influence their behavior. Being able to measure those signals and how cells respond to them through downstream molecular signaling networks could help scientists learn much more about how cells work, including what happens as they age or become diseased.

Right now, this kind of comprehensive study is not possible because current techniques for imaging cells are limited to just a handful of different molecule types within a cell at one time. However, MIT researchers have developed an alternative method that allows them to observe up to seven different molecules at a time, and potentially even more than that.

“There are many examples in biology where an event triggers a long downstream cascade of events, which then causes a specific cellular function,” says Edward Boyden, the Y. Eva Tan Professor in Neurotechnology. “How does that occur? It’s arguably one of the fundamental problems of biology, and so we wondered, could you simply watch it happen?”

Scientists at the University of Bath have used nature as inspiration in developing a new tool that will help researchers develop new pharmaceutical treatments in a cleaner, greener, and less expensive way.

Drug treatments often work by binding to proteins involved in disease and blocking their activity, which either reduces symptoms or treats the disease.

Rather than using conventional small molecules as drugs, which are not well suited to blocking interactions between proteins, the pharmaceutical industry is now investigating the potential of making drugs using small proteins known as ‘peptides,’ which work in a similar way.

As researchers, developers, policymakers and others grapple with navigating socially beneficial advanced technology transitions — especially those associated with artificial intelligence, DNA-based technologies, and quantum technologies — there are valuable lessons to be drawn from nanotechnology. These lessons underscore an urgent need to foster collaboration, engagement and partnerships across disciplines and sectors, together with bringing together people, communities, and organizations with diverse expertise, as they work together to realize the long-term benefits of transformative technologies.

Scientists have developed a novel approach that allows stem cells to be turned into retinal ganglion cells that are capable of migrating and surviving in the eye’s retina. This approach presents a promising new treatment strategy for diseases like glaucoma, in which the loss of retinal ganglion cells caused by the disease leads to irreversible vision loss.

Glaucoma is one of the leading causes of blindness worldwide, and vision loss, due to the loss of retinal ganglion cells (RGCs), cannot currently be reversed with any treatment. Some studies have looked at replacing RGCs through cell transplants, but this process is still in the research and development stage and fraught with limitations that highlight a need for a more precise manner of effectively repopulating these cells in the retina. Now, a multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.

In their new study, researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and surviving into the eye’s retina. They conducted their study on the adult mouse retina, but the work’s implications could one day be applied to human retina, according to the researchers who published their findings November 6th in Proceedings of the National Academy of Sciences.